As many as 40% of patients with cancer develop hiccups — often unbeknownst to their oncologist. But even if recognized, hiccups may not be treated effectively, according to a national survey of cancer care clinicians.
When poorly controlled, persistent hiccups can affect a patient’s quality of life, with 40% of survey respondents considering chronic hiccups “much more” or “somewhat more” severe than nausea and vomiting.
Overall, the findings indicate that patients with cancer who develop persistent hiccups are “truly suffering,” the authors write.
The survey results were published online recently in the American Journal of Hospice & Palliative Medicine.
Hiccups may simply be a nuisance for most, but these spasms can become problematic for patients with cancer, leading to sleep deprivation, fatigue, aspiration pneumonia, compromised food intake, weight loss, pain, even death.
Hiccups can develop when the nerve that controls the diaphragm becomes irritated, which can be triggered by certain chemotherapy drugs.
Yet few studies have focused on hiccups in patients with cancer and none, until now, has sought the perspectives of cancer care clinicians.
Aminah Jatoi, MD, medical oncologist with the Mayo Clinic in Rochester, Minnesota and two Mayo colleagues developed a survey, alongside MeterHealth, which Medscape distributed to clinicians with an interest in cancer care.
The survey gauged clinicians’ awareness or lack of awareness about clinically significant hiccups as well as treatments for hiccups and whether they consider hiccups an unmet palliative need.
A total of 684 clinicians completed two eligibility screening questions, which required them to have cared for more than 10 patients with cancer in the past 6 months with clinically significant hiccups (defined as hiccups that lasted more than 48 hours or occurred from cancer or cancer care).
Among 113 eligible healthcare professionals, 90 completed the survey, including 42 physicians, 29 nurses, 15 nurse practitioners, and 4 physician assistants.
The survey revealed three key issues. The first: hiccups appear to be an underrecognized issue.
Among healthcare professionals who answered the eligibility screening questions, fewer than 20% reported caring for more than 10 patients with cancer in the past 6 months who had persistent hiccups. Most of these clinicians reported caring for over 1000 patients a year.
Given that 15%-40% of patients with cancer report hiccups, this finding suggests that hiccups are not widely recognized by healthcare professionals.
Second, the survey data showed that hiccups often increase patients’ anxiety, fatigue, and sleep problems and can decrease productivity at work or school.
In fact, when comparing hiccups to nausea and vomiting — sometimes described as one of the most severe side effects of cancer care — 40% of respondents rated hiccups as “much more” or “somewhat more” severe than nausea and vomiting for their patients and 38% rated the severity of the two issues as “about the same.”
Finally, even when hiccups are recognized and treated, about 20% of respondents said that current therapies are not very effective, and more treatment options are needed.
Among the survey respondents, the most frequently prescribed medications for chronic hiccups were the antipsychotic chlorpromazine, the muscle relaxant baclofen (Lioresal), the antiemetic metoclopramide (Metozolv ODT, Reglan), and the anticonvulsants gabapentin (Neurontin) and carbamazepine (Tegretol).
Survey respondents who provided comments about current treatments for hiccups highlighted a range of challenges. One respondent said, “When current therapies do not work, it can be very demoralizing to our patients.” Another said, “I feel like it is a gamble whether treatment for hiccups will work or not.”
Still another felt that while current treatments work “quite well to halt hiccups,” they come with side effects which can be “quite severe.”
These results “clearly point to the unmet needs of hiccups in patients with cancer and should prompt more research aimed at generating more palliative options,” the authors say.
This research had no commercial funding. MeterHealth reviewed the manuscript and provided input on the accuracy of methods and results. Jatoi reports serving on an advisory board for MeterHealth (honoraria to institution).
Am J Hosp Palliat Med. Published online September 29, 2022. Abstract
For more from Medscape Oncology, join us on Twitter and Facebook
Source: Read Full Article